Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends

A new study has found that the cardioprotective drug dexrazoxane significantly reduces heart damage caused by chemotherapy in pediatric cancer patients 15 years or more after treatment ends. The research, led by Erin Mobley from the University of Florida College of Medicine, is the first large, long-term study suggesting that receiving dexrazoxane may change how doctors follow survivors for decades after treatment.

The findings could help guide prescribing recommendations and provide reassurance to families and patients about the long-term effects of cancer treatment on young patients. The study, which followed nearly 900 childhood cancer survivors, found that patients who received dexrazoxane had significantly healthier hearts compared to those who did not. This could potentially lead to reduced echocardiogram screenings for many survivors as they age.

Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — read the original for the full account.